Intervention not reported
HDL‐C (mg/dL) · people with hyperlipidaemia
1 finding from 1 review
Intervention not reported
Triglycerides (mg/dL) · people with hyperlipidaemia
1 finding from 1 review
Mean pressure gradient (mmHg) Better indicated by lower scores. · patients with aortic valve stenosis
Statin showed no clear difference in mean pressure gradient (mmHg) Better indicated by lower scores. compared with placebo (low certainty).
1 finding from 1 review
Valve area (cm2) Better indicated by higher scores. · patients with aortic valve stenosis
Statin showed no clear difference in valve area (cm2) Better indicated by higher scores. compared with placebo (low certainty).
1 finding from 1 review
Aortic jet velocity (m/s) · patients with aortic valve stenosis
Statin showed no clear difference in aortic jet velocity (m/s) compared with placebo (low certainty).
1 finding from 1 review
Freedom from valve replacement · patients with aortic valve stenosis
Statin showed no clear difference in freedom from valve replacement compared with placebo (moderate certainty).
1 finding from 1 review
All cardiovascular death · patients with aortic valve stenosis
Statin showed no clear difference in death from cardiovascular cause compared with placebo (low certainty).
1 finding from 1 review
Hospitalisation for any reason · patients with aortic valve stenosis
It is very uncertain whether statin changes hospitalisation for any reason compared with placebo (very low certainty).
1 finding from 1 review
Adverse events ‐ Muscle pain · patients with aortic valve stenosis
Statin showed no clear difference in adverse events ‐ Muscle pain compared with placebo (moderate certainty).
1 finding from 1 review
Number of new diagnoses · vulnerable population: senior 65 years of age or older
Screening probably leads to higher number of new diagnoses: systematic screening vs routine practice compared with routine practice (moderate certainty).
2 findings from 1 review
Number of new diagnoses · vulnerable population: senior 65 years of age or older
Systematic screening showed no clear difference in number of new diagnoses compared with opportunistic screening (low certainty).
1 finding from 1 review
Intervention not reported
Combined CVD death, non‐fatal MI, or non‐fatal stroke · patients in primary prevention of cardiovascular disease events
The intervention probably leads to lower combined CVD death, non‐fatal MI, or non‐fatal stroke (moderate certainty).
1 finding from 1 review
Intervention not reported
Combined coronary heart disease death or non‐fatal MI · patients in primary prevention of cardiovascular disease events
The intervention probably leads to lower combined coronary heart disease death or non‐fatal MI (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall mortality · patients in primary prevention of cardiovascular disease events
The intervention showed no clear difference in overall mortality (low certainty).
1 finding from 1 review
Intervention not reported
Non‐CVD mortality · patients in primary prevention of cardiovascular disease events
The intervention showed no clear difference in non‐CVD mortality (low certainty).
1 finding from 1 review
Intervention not reported
Discontinuation of therapy due to adverse effects · patients in primary prevention of cardiovascular disease events
It is very uncertain whether the intervention changes discontinuation of therapy due to adverse effects (very low certainty).
1 finding from 1 review
All‐cause mortality · general population including those at moderate to high risk of CVD, mean age between 30 and 75
Systematic screening showed no clear difference in all‐cause mortality compared with no/opportunistic screening (low certainty).
1 finding from 1 review
Stroke · general population including those at moderate to high risk of CVD, mean age between 30 and 75
Systematic screening showed no clear difference in stroke (total) compared with no/opportunistic screening (low certainty).
1 finding from 1 review
Total coronary heart disease · general population including those at moderate to high risk of CVD, mean age between 30 and 75
Systematic screening showed no clear difference in coronary heart disease (total) compared with no/opportunistic screening (low certainty).
1 finding from 1 review
Cholesterol mg/dL · general population including those at moderate to high risk of CVD, mean age between 30 and 75
1 finding from 1 review